KEZAR LIFE SCIENCES INC (KZR) Stock News
NASDAQ:KZR - Nasdaq - US49372L2097 - Common Stock - Currency: USD
KZR Latest News, Press Relases and Analysis
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty
On Tuesday, Citi downgraded Prime Medicine Inc. (NASDAQ:PRME) from a Buy to a Neutral rating while also significantly reducing its price target from $10 to $1.50. Citi said that this adjustment reflects that the company’s shares are trading near cash, which shows the market’s uncertainty on Prime Medicine’s path to potential value inflection. Despite implementing […]
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ:KZR) just reported results for the second quarter o...
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use.
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q2 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the second quarter of 2024.
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kezar Life Sciences (NASDAQ:KZR) just reported results for the first quarter of...
KZR Stock Earnings: Kezar Life Sciences Beats EPS for Q1 2024
KZR stock results show that Kezar Life Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
On Thursday, Kezar Life Sciences, Inc (NASDAQ:KZR) decided to terminate the PALIZADE Phase 2b trial in patients with active lupus nephritis (LN) and focus clinical development efforts on zetomipzomib in autoimmune hepatitis (AIH). Last week, the FDA placed a clinical hold on the company’s zetomipzomib Investigational New Drug (IND) application for LN following a review of emerging safety data, including an assessment of four Grade 5 (fatal or death) serious adverse events (SAEs) that occurred du
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths
On Friday, Kezar Life Sciences Inc. (NASDAQ:KZR) announced that it was informed via teleconference with the FDA that the zetomipzomib Investigational New Drug (IND) application for lupus nephritis (LN) has been placed on clinical hold. Lupus nephritis is a type of kidney disease caused by systemic lupus erythematosus link (SLE or lupus). Lupus is an autoimmune disease link—a disorder in which the body’s immune system attacks the body’s cells and organs. The action follows Kezar’s communication t
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Kezar Life Sciences Announces Cessation of Enrollment and Dosing in the Phase 2b PALIZADE Trial of Zetomipzomib in Active Lupus Nephritis Patients
Kezar Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
